Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CMD-003 |
| Synonyms | |
| Therapy Description |
CMD-003 (baltaleucel-T) comprises autologous Epstein-Barr virus (EBV) specific T-cells, which potentially leads to increased death of EBV-associated tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CMD-003 | Baltaleucel-T | CMD-003 (baltaleucel-T) comprises autologous Epstein-Barr virus (EBV) specific T-cells, which potentially leads to increased death of EBV-associated tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02763254 | Phase II | CMD-003 | Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC) | Terminated | USA | 0 |